{
    "id": 25944,
    "fullName": "KIT exon17",
    "impact": "unknown",
    "proteinEffect": "unknown",
    "geneVariantDescriptions": [
        {
            "description": "KIT exon 17 (amino acids 788-828) indicates an unspecified mutation has occurred in exon 17 of the KIT gene.",
            "references": [
                {
                    "id": 275,
                    "pubMedId": null,
                    "title": "External Reference Not Available (N/A)",
                    "url": "https://ckb.jax.org/about/glossaryOfTerms"
                }
            ]
        }
    ],
    "type": "category",
    "gene": {
        "id": 3815,
        "geneSymbol": "KIT",
        "terms": [
            "KIT",
            "C-Kit",
            "CD117",
            "MASTC",
            "PBT",
            "SCFR"
        ]
    },
    "variant": "exon17",
    "createDate": "01/18/2017",
    "updateDate": "11/14/2019",
    "referenceTranscriptCoordinates": null,
    "partnerGenes": [
        
    ],
    "evidence": [
        {
            "id": 14505,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I trial, PLX9486 and Pexidartinib (PLX3397) combination therapy demonstrated safety and preliminary efficacy, resulted in a partial response rate of 8.3% (1/12) and progression-free survival not yet reached in patients with advanced solid tumors, 11 of these patients had gastrointestinal stromal tumor that progressed on Gleevec (imatinib mesylate), and most harbored KIT exon 11 and exon 17 mutations (Journal of Clinical Oncology 36, no. 15_suppl (May 20 2018) 11509-11509; NCT02401815).",
            "molecularProfile": {
                "id": 27079,
                "profileName": "KIT exon17"
            },
            "therapy": {
                "id": 7099,
                "therapyName": "Pexidartinib + PLX9486",
                "synonyms": null
            },
            "indication": {
                "id": 9253,
                "name": "gastrointestinal stromal tumor",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 11669,
                    "pubMedId": null,
                    "title": "A phase I pharmacokinetic (PK) and pharmacodynamic (PD) study of PLX9486 alone and in combination (combo) with the KIT inhibitors pexidartinib (pexi) or sunitinib (su) in patients (Pts) with advanced solid tumors and gastrointestinal stromal tumor (GIST).",
                    "url": "http://ascopubs.org/doi/abs/10.1200/JCO.2018.36.15_suppl.11509#affiliationsContainer"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 9776,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I trial, Ayvakit (avapritinib) demonstrated preliminary antitumor activity in gastrointestinal stromal tumor patients harboring KIT mutations, with reduced tumor burden in 38% (5/13) of patients, including 1 partial response and 4 stable diseases, and 3 of the 5 responding patients harbored KIT exon 17 mutations (EORTC-NCI-AACR 2016, Abs 6LBA).",
            "molecularProfile": {
                "id": 27079,
                "profileName": "KIT exon17"
            },
            "therapy": {
                "id": 2941,
                "therapyName": "Avapritinib",
                "synonyms": null
            },
            "indication": {
                "id": 9253,
                "name": "gastrointestinal stromal tumor",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 7597,
                    "pubMedId": null,
                    "title": "Preliminary safety and activity in a first-in-human phase 1 study of BLU-285, a potent, highly-selective inhibitor of KIT and PDGFRa activation loop mutants in advanced gastrointestinal stromal tumor (GIST)",
                    "url": "http://www.ecco-org.eu/Events/ENA2016/Searchable-Programme#anchorScpr"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 12308,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Ayvakit (avapritinib) inhibited Kit phosphorylation and proliferation of various tumor cell lines harboring KIT exon 17 mutations in culture, and induced tumor regression in an allograft animal model (PMID: 29093181).",
            "molecularProfile": {
                "id": 27079,
                "profileName": "KIT exon17"
            },
            "therapy": {
                "id": 2941,
                "therapyName": "Avapritinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 10301,
                    "pubMedId": 29093181,
                    "title": "A precision therapy against cancers driven by KIT/PDGFRA mutations.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29093181"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 14502,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I trial, PLX9486 demonstrated safety and preliminary efficacy, resulted in a progression-free survival of more than 24 weeks and partial response in 8.3% (2/24) of patients with advanced solid tumors, 20 of these patients had gastrointestinal stromal tumor that progressed on Gleevec (imatinib mesylate), and most harbored KIT exon 11 and exon 17 mutations (Journal of Clinical Oncology 36, no. 15_suppl (May 20 2018) 11509-11509; NCT02401815).",
            "molecularProfile": {
                "id": 27079,
                "profileName": "KIT exon17"
            },
            "therapy": {
                "id": 2602,
                "therapyName": "PLX9486",
                "synonyms": null
            },
            "indication": {
                "id": 9253,
                "name": "gastrointestinal stromal tumor",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 11669,
                    "pubMedId": null,
                    "title": "A phase I pharmacokinetic (PK) and pharmacodynamic (PD) study of PLX9486 alone and in combination (combo) with the KIT inhibitors pexidartinib (pexi) or sunitinib (su) in patients (Pts) with advanced solid tumors and gastrointestinal stromal tumor (GIST).",
                    "url": "http://ascopubs.org/doi/abs/10.1200/JCO.2018.36.15_suppl.11509#affiliationsContainer"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 14506,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I trial, PLX9486 treatment resulted in partial response with 33% decrease of tumor size after 4 cycles of therapy in a patient with gastrointestinal stromal tumor harboring a primary KIT exon 11 mutation and a secondary KIT exon 17 mutation, who progressed on prior Gleevec (imatinib mesylate) and Sutent (sunitinib) therapies (CTOS Annual Meeting, Nov 2017, abstract # 2771952).",
            "molecularProfile": {
                "id": 30032,
                "profileName": "KIT exon11 KIT exon17"
            },
            "therapy": {
                "id": 2602,
                "therapyName": "PLX9486",
                "synonyms": null
            },
            "indication": {
                "id": 9253,
                "name": "gastrointestinal stromal tumor",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 11674,
                    "pubMedId": null,
                    "title": "A PHASE 1 PHARMACOKINETIC (PK) AND PHARMACODYNAMIC (PD) STUDY OF PLX9486, ANOVEL KIT INHIBITOR WITH POTENT ACTIVITY AGAINST EXON 17/18 ACTIVATION LOOP MUTATIONS IN PATIENTS WITH GASTROINTESTINAL STROMAL TUMOR (GIST)",
                    "url": "https://www.ctos.org/Portals/0/PDF/2017%20CTOS%20Final%20Program.pdf"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "molecularProfiles": [
        {
            "id": 27079,
            "profileName": "KIT exon17",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 30032,
            "profileName": "KIT exon11 KIT exon17",
            "profileTreatmentApproaches": [
                
            ]
        }
    ],
    "allTranscriptCoordinates": [
        
    ]
}